PL3113773T3 - Krystaliczne postaci grapiprantu - Google Patents

Krystaliczne postaci grapiprantu

Info

Publication number: PL3113773T3
Authority: PL; Poland
Prior art keywords: grapiprant; crystalline forms; crystalline; forms
Prior art date: 2014-03-06

Application number

PL15758500T

Other languages

English (en)

Inventor

Tamara NEWBOLD

Melissa SMITH

Chris SEEKAMP

Robert Wenslow

Xia LU

Original Assignee

Aratana Therapeutics Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-06

Filing date

2015-03-05

Publication date

2020-05-18

2015-03-05 Application filed by Aratana Therapeutics Inc. filed Critical Aratana Therapeutics Inc.

2020-05-18 Publication of PL3113773T3 publication Critical patent/PL3113773T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Led Devices (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Ceramic Products (AREA)
Inorganic Insulating Materials (AREA)

PL15758500T 2014-03-06 2015-03-05 Krystaliczne postaci grapiprantu PL3113773T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201461949006P	2014-03-06	2014-03-06
US201461996961P	2014-07-30	2014-07-30
PCT/US2015/019043 WO2015134797A1 (en)	2014-03-06	2015-03-05	Crystalline forms of grapiprant
EP15758500.1A EP3113773B1 (en)	2014-03-06	2015-03-05	Crystalline forms of grapiprant

Publications (1)

Publication Number	Publication Date
PL3113773T3 true PL3113773T3 (pl)	2020-05-18

Family

ID=54016295

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL19156369.1T PL3511000T3 (pl)	2014-03-06	2015-03-05	Krystaliczne postaci x2 grapiprantu
PL15758500T PL3113773T3 (pl)	2014-03-06	2015-03-05	Krystaliczne postaci grapiprantu
PL17193737T PL3295941T3 (pl)	2014-03-06	2015-03-05	Sposób wytwarzania postaci a grapiprantu

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL19156369.1T PL3511000T3 (pl)	2014-03-06	2015-03-05	Krystaliczne postaci x2 grapiprantu

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL17193737T PL3295941T3 (pl)	2014-03-06	2015-03-05	Sposób wytwarzania postaci a grapiprantu

Country Status (16)

Country	Link
US (1)	US9265756B2 (pl)
EP (4)	EP3113773B1 (pl)
JP (2)	JP6535683B2 (pl)
KR (2)	KR101697914B1 (pl)
CN (11)	CN107501262A (pl)
AU (1)	AU2015227064B2 (pl)
CA (10)	CA2997703A1 (pl)
DK (3)	DK3113773T3 (pl)
ES (3)	ES2755396T3 (pl)
MX (2)	MX388969B (pl)
NZ (3)	NZ733225A (pl)
PL (3)	PL3511000T3 (pl)
PT (3)	PT3511000T (pl)
RU (1)	RU2638931C1 (pl)
TW (1)	TWI537270B (pl)
WO (1)	WO2015134797A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT3113774T (pt)	2014-03-06	2022-02-28	Elanco Animal Health Incorporated	Composições de grapiprant e métodos de utilização das mesmas
US12109218B2 (en)	2014-12-09	2024-10-08	Aratana Therapeutics, Inc.	Compositions of grapiprant and methods for using the same
US10973834B2 (en)	2018-04-16	2021-04-13	Arrys Therapeutics, Inc.	EP4 inhibitors and use thereof
WO2020014445A1 (en) *	2018-07-11	2020-01-16	Arrys Therapeutics, Inc.	Ep4 inhibitors and synthesis thereof
WO2020014465A1 (en) *	2018-07-11	2020-01-16	Arrys Therapeutics, Inc.	Polymorphic compounds and uses thereof
US11254675B2 (en) *	2019-08-12	2022-02-22	Cadila Healthcare Limited	Process for preparation of grapiprant
WO2021226162A1 (en)	2020-05-05	2021-11-11	Arrys Therapeutics, Inc.	Ep4 antagonists and their use in the treatment of proliferative diseases
CN116283959A (zh) *	2021-12-10	2023-06-23	江苏慧聚药业股份有限公司	格拉匹纶新晶型及其制备

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HN2001000224A (es)	2000-10-19	2002-06-13	Pfizer	Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
KR100911073B1 (ko) *	2005-03-11	2009-08-06	라퀄리아 파마 인코포레이티드	이미다졸 유도체의 결정 형태
KR101368519B1 (ko) *	2005-05-23	2014-02-27	노파르티스 아게	결정형 및 기타 형태의 4-아미노-5-플루오로-3-［6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일］-1ｈ-퀴놀린-2-온 락트산염
JP5069752B2 (ja)	2006-12-15	2012-11-07	グラクソグループリミテッド	Ｅｐ４受容体アゴニストとしてのベンズアミド誘導体
CA2733247C (en) *	2008-08-14	2018-04-03	Beta Pharma Canada Inc.	Heterocyclic amide derivatives as ep4 receptor antagonists
KR20190015614A (ko)	2011-05-18	2019-02-13	라퀄리아 파마 인코포레이티드	4-｛[4-(｛[4-(2,2,2-트리플루오로에톡시)-1,2-벤즈이속사졸-3-일]옥시｝메틸)피페리딘-1-일]메틸｝-테트라히드로-2h-피란-4-카르복실산의 다형

2015
- 2015-03-05 CN CN201710831540.8A patent/CN107501262A/zh active Pending
- 2015-03-05 DK DK15758500T patent/DK3113773T3/da active
- 2015-03-05 CA CA2997703A patent/CA2997703A1/en not_active Abandoned
- 2015-03-05 KR KR1020167024256A patent/KR101697914B1/ko active Active
- 2015-03-05 CN CN202110197159.7A patent/CN113087705A/zh active Pending
- 2015-03-05 KR KR1020177000896A patent/KR101771385B1/ko active Active
- 2015-03-05 US US14/639,916 patent/US9265756B2/en active Active
- 2015-03-05 CA CA2997692A patent/CA2997692A1/en not_active Abandoned
- 2015-03-05 ES ES15758500T patent/ES2755396T3/es active Active
- 2015-03-05 ES ES17193737T patent/ES2816057T3/es active Active
- 2015-03-05 EP EP15758500.1A patent/EP3113773B1/en active Active
- 2015-03-05 MX MX2018003837A patent/MX388969B/es unknown
- 2015-03-05 PL PL19156369.1T patent/PL3511000T3/pl unknown
- 2015-03-05 CN CN201710832497.7A patent/CN107759591A/zh not_active Withdrawn
- 2015-03-05 CA CA2997697A patent/CA2997697A1/en not_active Abandoned
- 2015-03-05 CN CN201710832416.3A patent/CN107759590A/zh not_active Withdrawn
- 2015-03-05 PT PT191563691T patent/PT3511000T/pt unknown
- 2015-03-05 CA CA2997718A patent/CA2997718A1/en active Pending
- 2015-03-05 CA CA2997746A patent/CA2997746A1/en not_active Abandoned
- 2015-03-05 CN CN201580002716.8A patent/CN105764508A/zh active Pending
- 2015-03-05 RU RU2016139096A patent/RU2638931C1/ru active
- 2015-03-05 CN CN201710832196.4A patent/CN107759589A/zh active Pending
- 2015-03-05 EP EP19156369.1A patent/EP3511000B1/en active Active
- 2015-03-05 PT PT157585001T patent/PT3113773T/pt unknown
- 2015-03-05 MX MX2016011023A patent/MX367376B/es active IP Right Grant
- 2015-03-05 CN CN201710831735.2A patent/CN107400132A/zh not_active Withdrawn
- 2015-03-05 CN CN201910653673.XA patent/CN110256426A/zh active Pending
- 2015-03-05 TW TW104107082A patent/TWI537270B/zh active
- 2015-03-05 JP JP2016555827A patent/JP6535683B2/ja active Active
- 2015-03-05 CA CA2997694A patent/CA2997694C/en active Active
- 2015-03-05 NZ NZ733225A patent/NZ733225A/en unknown
- 2015-03-05 EP EP19156370.9A patent/EP3520790A1/en not_active Withdrawn
- 2015-03-05 WO PCT/US2015/019043 patent/WO2015134797A1/en not_active Ceased
- 2015-03-05 CA CA3168877A patent/CA3168877A1/en active Pending
- 2015-03-05 NZ NZ724923A patent/NZ724923A/en unknown
- 2015-03-05 DK DK19156369.1T patent/DK3511000T3/da active
- 2015-03-05 CA CA3105571A patent/CA3105571A1/en active Pending
- 2015-03-05 PL PL15758500T patent/PL3113773T3/pl unknown
- 2015-03-05 CN CN201710831795.4A patent/CN107501263A/zh not_active Withdrawn
- 2015-03-05 ES ES19156369T patent/ES2919346T3/es active Active
- 2015-03-05 CA CA2997741A patent/CA2997741A1/en not_active Abandoned
- 2015-03-05 DK DK17193737.8T patent/DK3295941T3/da active
- 2015-03-05 CA CA2941019A patent/CA2941019A1/en not_active Withdrawn
- 2015-03-05 PL PL17193737T patent/PL3295941T3/pl unknown
- 2015-03-05 CN CN201710831743.7A patent/CN107540671A/zh not_active Withdrawn
- 2015-03-05 AU AU2015227064A patent/AU2015227064B2/en active Active
- 2015-03-05 EP EP17193737.8A patent/EP3295941B1/en active Active
- 2015-03-05 NZ NZ733234A patent/NZ733234A/en unknown
- 2015-03-05 PT PT171937378T patent/PT3295941T/pt unknown
- 2015-03-05 CN CN201710831494.1A patent/CN107573339A/zh not_active Withdrawn
2017
- 2017-11-10 JP JP2017217662A patent/JP2018065819A/ja active Pending

Also Published As

Publication number	Publication date
MX367376B (es)	2019-08-16
DK3511000T3 (da)	2022-05-30
CN107400132A (zh)	2017-11-28
PL3295941T3 (pl)	2020-11-16
JP2017507161A (ja)	2017-03-16
EP3113773A4 (en)	2017-05-10
EP3295941B1 (en)	2020-07-22
EP3511000B1 (en)	2022-04-27
ES2816057T3 (es)	2021-03-31
CN107759590A (zh)	2018-03-06
EP3295941A1 (en)	2018-03-21
NZ724923A (en)	2018-03-23
CA2997703A1 (en)	2015-09-11
CA3168877A1 (en)	2015-09-11
AU2015227064A1 (en)	2016-10-27
KR101697914B1 (ko)	2017-01-18
CN107501262A (zh)	2017-12-22
CN107501263A (zh)	2017-12-22
PT3113773T (pt)	2019-11-12
CN113087705A (zh)	2021-07-09
CN105764508A (zh)	2016-07-13
CA2997697A1 (en)	2015-09-11
TW201538500A (zh)	2015-10-16
CA3105571A1 (en)	2015-09-11
AU2015227064B2 (en)	2017-05-11
CA2941019A1 (en)	2015-09-11
US20150250774A1 (en)	2015-09-10
NZ733225A (en)	2018-03-23
NZ733234A (en)	2018-08-31
PT3295941T (pt)	2020-08-25
CA2997718A1 (en)	2015-09-11
WO2015134797A1 (en)	2015-09-11
CA2997694A1 (en)	2015-09-11
TWI537270B (zh)	2016-06-11
KR20170008889A (ko)	2017-01-24
DK3113773T3 (da)	2019-11-18
CN110256426A (zh)	2019-09-20
EP3113773A1 (en)	2017-01-11
CA2997694C (en)	2021-04-06
CN107540671A (zh)	2018-01-05
US9265756B2 (en)	2016-02-23
CN107759591A (zh)	2018-03-06
KR101771385B1 (ko)	2017-08-24
MX388969B (es)	2025-03-20
CA2997741A1 (en)	2015-09-11
EP3113773B1 (en)	2019-09-18
PL3511000T3 (pl)	2022-08-22
MX2016011023A (es)	2016-11-28
ES2755396T3 (es)	2020-04-22
KR20160106779A (ko)	2016-09-12
CN107573339A (zh)	2018-01-12
CN107759589A (zh)	2018-03-06
CA2997746A1 (en)	2015-09-11
CA2997692A1 (en)	2015-09-11
ES2919346T3 (es)	2022-07-26
PT3511000T (pt)	2022-05-25
EP3520790A1 (en)	2019-08-07
RU2638931C1 (ru)	2017-12-19
JP2018065819A (ja)	2018-04-26
DK3295941T3 (da)	2020-08-24
EP3511000A1 (en)	2019-07-17
JP6535683B2 (ja)	2019-06-26

Publication	Publication Date	Title
IL251584A0 (en)	2017-06-29	Dihydropyrrolopyridines ror-gamma inhibitors
EP3136857A4 (en)	2017-09-20	Crystalline form of baricitinib
IL246902A0 (en)	2016-09-29	Dihydropyrrolopyridine ror–gamma inhibitors
SG11201609265RA (en)	2016-12-29	Characterizing states of subject
ZA201700880B (en)	2020-01-29	Polymorphs of selinexor
IL246385B (en)	2019-07-31	Crystalline forms of efitinib di-malate
SI3845221T1 (sl)	2024-03-29	Trdne oblike sofosbuvirja
PT3113773T (pt)	2019-11-12	Formas cristalinas do grapiprant
SI3380554T2 (sl)	2024-01-31	Kristalne oblike per-kloro-gama-ciklodekstrinov
SG10202101979TA (en)	2021-04-29	Crystalline forms of c21h22ci2n4o2
IL246979A0 (en)	2016-09-29	Crystalline forms of sofosbuvir
HUE066360T2 (hu)	2024-07-28	Eravaciklin kristályformái
GB201419174D0 (en)	2014-12-10	Crystalline forms
EP3207034A4 (en)	2018-03-21	Anhydrous crystalline form of s-equol
IL253479A0 (en)	2017-09-28	Crystalline forms of efinconazole
IL249130A0 (en)	2017-01-31	Preparation of piperidine-4-carbthioamide
PL3350179T3 (pl)	2021-08-02	Krystaliczne postacie
IL249332A0 (en)	2017-02-28	Crystalline forms of sofosbuvir
PL3137475T3 (pl)	2019-01-31	Oczyszczanie epidaunorubicyny
GB201404705D0 (en)	2014-04-30	Theory of Conceptual art
GB201417348D0 (en)	2014-11-12	Prodrugs of lxazomib
GB201417347D0 (en)	2014-11-12	Prodrugs of delanzomib